3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

PREVALENCE OF SEROLOGIC MARKERS OF HEPATITIS B AND C VIRUSES AMONG HIV INFECTED PATIENTS IN IPEC/FIOCRUZ – RIO DE JANEIRO, BRAZIL

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPe1.1C36

Silva A.C.M., Moreira R.I., Soares J.C., Grinsztejn B., d'Almeida R.G., Scarpellini B., Georg I., Pilotto J.H.
Instituto de Pesquisa Clínica Evandro Chagas / FIOCRUZ, Rio de Janeiro, Brazil

INTRODUCTION: To assess the prevalence of serologic markers of Hepatitis B and C viruses among HIV- infected subjects followed in Instituto de Pesquisa Clinica Evandro Chagas (IPEC)/FIOCRUZ - Rio de Janeiro, Brazil, from January, 1987 to November, 2004.

METHODS: We examined data from all HIV-infected subjects from January, 1987, to November, 2004 (N=2005). Serologic markers results for hepatitis B and C have been collected by chart-review and entered into a database. Hepatitis B data have been used to classify groups according to the Hepatitis B Panel, CDC-Atlanta, as: susceptible, immune due to natural infection, immune due to hepatitis B vaccination, acutely infected, chronically infected and anti-HBc positive, which may have a broad interpretation. IgM anti-HBc has only been considered to define acute infection, when positive. Anti-HCV serology has been evaluated as positive or negative.

RESULTS: No data about serologic markers of Hepatitis B was found for 556 subjects (27.7%). Data from 362 (18.5%) subjects did not meet any criteria for CDC classification. Thus, only 1087 subjects (54.2%) have been classified, being 666 (45.9%) susceptible, 218 (15%) immune due to natural infection, 49 (3.4%) immune due to hepatitis B vaccination, 6 (0.4%) acutely infected, 31 (2.1%) chronically infected) and 117 (8.1%) presented a positive Anti-HBc, with a broad interpretation. No data about serologic markers of Hepatitis C have been found for 963 subjects (48%). From the remaining 1042 subjects (52%), 114 (10.9%) were Anti-HCV positive and 928 (89.1%) were Anti-HCV negative.

CONCLUSIONS: Our data shows a large proportion of patients susceptible to hepatitis B infection. In Brazil, vaccination programs are more focused on childhood and access of adults to hepatitis B is still limited. Due to the impact of HBV/HCV in HIV-infection morbidity and mortality, all HIV infected individuals must be tested for HBV/HCV for appropriate management and treatment.

Download PDF of this abstract.

050724
Clinical | TuPe1.1C36 | Anita Campos Mendonça Silva
Hepatitis viruses

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.